Maynard Um
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) Tops Q1 EPS by 10c
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $20 at BofA Securities
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Raised to $15 at RBC Capital
-
-
-
-
-
-
-
Goldman: ' the inability to fully screen at-risk patients could be a factor in the competitive dynamics in ATTR'
-
-
-
-
-
-
-
Jones Trading Downgrades Intellia Therapeutics (NTLA) to Hold
-
-
-
-
-
-
-
BofA Securities Downgrades Intellia Therapeutics (NTLA) to Neutral, 'FDA pause lowers contribution from key value driver'
-
-
-
-
-
-
-
Bernstein SocGen Group Downgrades Intellia Therapeutics (NTLA) to Market Perform
-
421,816 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

